News | May 09, 2026
Lonza surges on biologics boom
Expands manufacturing push & locks in major growth deals
Expands manufacturing push & locks in major growth deals
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
